Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis

Objective Preclinical studies suggest a role for lysophosphatidic acid ( LPA ) in the pathogenesis of systemic sclerosis ( SS c). We undertook this study to assess SAR 100842, a potent selective oral antagonist of the LPA 1 receptor, for safety, biomarkers, and clinical efficacy in patients with diffuse cutaneous SS c (dc SS c). Methods An 8‐week double‐blind, randomized, placebo‐controlled study followed by a 16‐week open‐label extension with...